| 182 | 0 | 76 |
| 下载次数 | 被引频次 | 阅读次数 |
本研究探讨了小白菊内酯(PTL)对卡波氏肉瘤相关疱疹病毒(KSHV)感染细胞(iSLK.219细胞和SK-RG细胞)迁移和侵袭的影响，并阐明其可能的分子机制。本研究将KSHV感染细胞分为空白对照组和PTL处理组，并进行了划痕实验、Transwell实验和Western blot实验。划痕实验结果显示，PTL处理组细胞划痕愈合率显著低于对照组(P<0.05);Transwell实验结果显示，PTL处理组KSHV感染细胞的迁移和侵袭能力显著低于对照组(P<0.05);Western blot实验结果显示，与对照组相比，PTL处理组MMP2、MMP9蛋白表达水平显著降低(P<0.05)。结果表明，PTL对KSHV感染细胞的迁移和侵袭具有抑制作用，其机制可能与其降低MMP2和MMP9的表达有关。
Abstract：This study investigated the effects of parthenolide(PTL) on the migration and invasion of kaposi's sarcoma-associated herpesvirus(KSHV) infected cells, specifically iSLK.219 cells and SK-RG cells, aiming to clarify its potential molecular mechanisms. KSHV-infected cells were divided into a blank control group and a PTL-treated group. Wound healing assays, Transwell assays, and Western blot analyses were conducted. The results of the wound healing assay indicated that the healing rate of cell scratches in the PTL group was significantly slower than that in the control group(P<0.05). Furthermore, the Transwell assay results demonstrated that the migration and invasion capabilities of KSHV-infected cells in the PTL group were significantly reduced compared to the control group(P<0.05). Western blot analyses revealed that, relative to the control group, the expression levels of MMP2 and MMP9 proteins were significantly decreased in the PTL group(P<0.05). These findings suggest that PTL exerts an inhibitory effect on the migration and invasion of KSHV-infected cells, potentially through the downregulation of MMP2 and MMP9 expression.
[1] BERWANGER A,STEIN S C,KANY A M,et al.Disrupting Kaposi’s sarcoma-associated herpesvirus (KSHV) latent replication with a small molecule inhibitor[J].J Med Chem,2023,66(15):10782-10790.
[2] LANGE P T,WHITE M C,DAMANIA B.Activation and evasion of innate immunity by gammaherpesviruses[J].J Mole Biol,2022,434(6):167214-167255.
[3] JARY A,VEYRI M,GOTHLAND A,et al.Kaposi’s sarcoma-associated herpesvirus,the etiological agent of all epidemiological forms of Kaposi’s sarcoma[J].Cancers,2021,13(24):6208-6231.
[4] YUAN H,LIU Z,WU X,et al.Social behavioral correlates of Kaposi sarcoma-associated herpesvirus infection among Han and Uygur populations in Xinjiang,China[J].J Med Virol,2019,91(3):457-462.
[5] POOLE C L,JAMES S H.Antiviral therapies for herpesviruses:current agents and new directions[J].Clin Ther,2018,40(8):1282-1298.
[6] K?YSIK K,PIETRASZEK A,KAREWICZ A,et al.Acyclovir in the treatment of herpes viruses-a review[J].Curr Med Chem,2020,27(24):4118-4137.
[7] CHEN E Y,RAGHUNATHAN V,PRASAD V.An overview of cancer drugs approved by the US food and drug administration based on the surrogate end point of response rate[J].JAMA Intern Med,2019,179(7):915-921.
[8] KROWN S E,MOSER C B,MACPHAIL P,et al.Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings:a three-arm,open-label,randomised,non-inferiority trial[J].The lancet,2020,395(10231):1195-1207.
[9] ?UDOMOVá M,BERCHOVá-BíMOVá K,MARZOCCO S,et al.Berberine in human oncogenic herpesvirus infections and their linked cancers[J].Viruses,2021,13(6):1014-1032.
[10] VASAN N,BASELGA J,HYMAN D M.A view on drug resistance in cancer[J].Nature,2019,575(7782):299-309.
[11] AN T,YIN H H,LU Y T,et al.The emerging potential of parthenolide nanoformulations in tumor therapy [J].Drug Des Devel Ther,2022,16:1255-1272.
[12] SZTILLER-SIKORSKA M,CZYZ M.Parthenolide as cooperating agent for anti-cancer treatment of various malignancies[J].Pharmaceuticals,2020,13(8):194-224.
[13] LI Y,XU H L,TAN X H,et al.Parthenolide inhibits proliferation of cells infected with Kaposi’s sarcoma-associated herpesvirus by suppression of the NF-κB signaling pathway[J].Arch Virol,2023,168(2):39-51.
[14] CAO D D,WU S Y,WANG X L,et al.Kaposi’s sarcoma-associated herpesvirus infection promotes proliferation of SH-SY5Y cells by the Notch signaling pathway[J].Cancer Cell Int,2021,21(1):577-582.
[15] PROVANCE O K,GEANES E S,LUI A J,et al.Disrupting interferon-alpha and NF-kappaB crosstalk suppresses IFITM1 expression attenuating triple-negative breast cancer progression[J].Cancer letters,2021,514:12-29.
[16] MARINO S,BISHOP R T,CARRASCO G,et al.Pharmacological inhibition of NFκB reduces prostate cancer related osteoclastogenesis in vitro and osteolysis ex vivo[J].Calcif Tissue Int,2019,105(2):193-204.
[17] IIDA-NORITA R,KAWAMURA M,SUZUKI Y,et al.Vasohibin-2 plays an essential role in metastasis of pancreatic ductal adenocarcinoma[J].Cancer science,2019,110(7):2296-2308.
[18] DING Y,LI S,GE W,et al.Design and synthesis of parthenolide and 5-fluorouracil conjugates as potential anticancer agents against drug resistant hepatocellular carcinoma[J].Eur J Med Chem,2019,183:111706-111720.
[19] CARLISI D,DE BLASIO A,DRAGO-FERRANTE R,et al.Parthenolide prevents resistance of MDA-MB231 cells to doxorubicin and mitoxantrone:the role of Nrf2[J].Cell Death Discov,2017,3:17078-17079.
[20] LIU M H,YANG Y,LIU D J,et al.Parthenolide increases the sensitivity of gastric cancer cells to chemotherapy[J].J Tradit Chin Med,2020,40(6):908-916.
[21] LI Y,ZHANG Y L,FU M M,et al.Parthenolide induces apoptosis and lytic cytotoxicity in Epstein-Barr virus-positive Burkitt lymphoma[J].Mol Med Rep,2012,6(3):477-482.
[22] LAKHERA S,DEVLAL K,GHOSH A,et al.Modelling the DFT structural and reactivity study of feverfew and evaluation of its potential antiviral activity against COVID-19 using molecular docking and MD simulations[J].Chem Zvesti,2022,76(5):2759-2776.
[23] ZOU Z H,SHAN H Z,SUN D M,et al.Parthenolide reveals an allosteric mode to inhibit the deISGylation activity of SARS-CoV-2 papain-like protease [J].Acta Biochim Biophys Sin,2022,54(8):1133-1139.
[24] BENASSI-ZANQUETA é,MARQUES C F,NOCCHI S R,et al.Parthenolide influences herpes simplex virus 1 replication in vitro[J].Intervirology,2018,61(1):14-22.
[25] YANG H L,HE F,JIELILI A,et al.A retrospective study of Kaposi’s sarcoma in Hotan region of Xinjiang,China[J].Medicine,2023,102(41):e35552.
[26] GATHERS D A,GALLOWAY E,KELEMEN K,et al.Primary effusion lymphoma:a clinicopathologic perspective[J].Cancers,2022,14(3):722-737.
[27] CHEN J,DAI L,GOLDSTEIN A,et al.Identification of new antiviral agents against Kaposi’s sarcoma-associated herpesvirus (KSHV) by high-throughput drug screening reveals the role of histamine-related signaling in promoting viral lytic reactivation[J].PLoS Pathog,2019,15(12):e1008156.
[28] ELBASANI E,GRAMOLELLI S,GüNTHER T,et al.Kaposi’s sarcoma-associated herpesvirus lytic replication is independent of anaphase-promoting complex activity[J].J Virol,2020,94(13):e02079-19.
[29] CHAN P K,NG H K,HUI M,et al.Presence of human herpesviruses 6,7,and 8 DNA sequences in normal brain tissue[J].J Med Virol,1999,59(4):491-495.
[30] BALDINI F,BAIOCCHINI A,SCHININà V,et al.Brain localization of Kaposi’s sarcoma in a patient treated by combination antiretroviral therapy[J].BMC Infect Dis,2013,21(13):600.
[31] TSO F Y,SAWYER A,KWON E H,et al.Kaposi’s sarcoma-associated herpesvirus infection of neurons in HIV-positive patients[J].J Infect Dis,2017,215(12):1898-1907.
[32] JHA H C,MEHTA D,LU J,et al.Gammaherpesvirus infection of human neuronal cells[J].MBio,2015,6(6):e01844-15.
[33] KONG X,LI D,MANSOURI A,et al.Bone marrow-derived SH-SY5Y neuroblastoma cells infected with Kaposi’s sarcoma-associated herpesvirus display unique infection phenotypes and growth properties[J].J Virol,2021,95(13):e0000321.
[34] CABRAL-PACHECO G A,GARZA-VELOZ I,CASTRUITA-DE LA ROSA C,et al.The roles of matrix metalloproteinases and their inhibitors in human diseases[J].Int J Mol Sci,2020,21(24):9739-9794.
[35] ALMUTAIRI S,KALLOUSH H M,MANOON N A,et al.Matrix metalloproteinases inhibitors in cancer treatment:an updated review (2013—2023)[J].Molecules,2023,28(14):5567-5598.
[36] QIAN L W,XIE J P,YE F C,et al.Kaposi’s sarcoma-associated herpesvirus infection promotes invasion of primary human umbilical vein endothelial cells by inducing matrix metalloproteinases[J].J Virol,2007,81(13):7001-7010.
基本信息:
中图分类号:R285
引用信息:
[1]王晓雯,雷浩杰,程淼,等.小白菊内酯对KSHV感染细胞迁移和侵袭的影响[J].塔里木大学学报,2025,37(02):84-91.
基金信息:
国家级大学生创新训练项目(202310757022); 塔里木大学校长基金硕士人才项目(TDZKSS202105)
2024-02-06
2024
2025-03-27
2024-04-24
2024
1
2025-04-15
2025-04-15